Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCG101 in HBV-related HCC
NCT05339321Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of SCG101 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Dose Limiting Toxicities at 28 days. Status: unknown.
02
Drugs
SCG101
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05339321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05339321.